Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity
AssigneeSiemens Healthcare Diagnostics Products GmbH
InventorsFrank Vitzthum, Herbert Schwarz
Life of this patent
Estimating the term…
Abstract
The present invention relates to a diagnostic method for identifying persons with genetically related hetero- or homozygous expression of the MR I variant of factor VII-activating protease (FSAP). The heterozygous or homozygous presence of an MR I polymorphism can be identified by a differential modulation of the FSAP activity.
Claims19
A method for identifying whether an individual shows heterozygous or homozygous expression of the Marburg I (MR I) variant of factor MI-activating protease (FSAP), comprising determining FSAP activity in a sample from the individual in the absence and in the presence of aprotinin, wherein aprotinin
- reduces FSAP activity, and
- reduces FSAP activity in samples from individuals with heterozygous or homozygous expression of the MR I variant of FSAP to a lesser extent than reduces FSAP activity in samples from individuals who do not express said MR I variant of FSAP.
A method for identifying whether an individual shows heterozygous or homozygous expression of the Marburg I (MR I) variant of factor VII-activating protease (FSAP), comprising determining FSAP activity in a sample from the individual in the absence and in the presence of a polyclonal or monoclonal anti-FSAP antibody, wherein the antibody
- reduces FSAP activity, and
- reduces FSAP activity in samples from individuals with heterozygous or homozygous expression of the MR I variant of FSAP to a lesser extent than the antibody reduces FSAP activity in samples from individuals who do not express said MR I variant of FSAP.
A method for identifying whether an individual shows heterozygous or homozygous expression of the Marburg I (MR I) variant of factor VII-activating protease (FSAP), comprising determining FSAP activity in a sample from the individual in the absence and in the presence of a monoclonal or polyclonal anti-FSAP antibody, wherein the antibody
- increases FSAP activity, and
- increases FSAP activity in samples from individuals with heterozygous or homozygous expression of the MR I variant of FSAP to a lesser extent than the antibody increases FSAP activity in samples from individuals who do not express said MR I variant of FSAP.
Dependencies are inferred from the claim text.